Video

Dr. David Silver discusses his experience with HIFU

Author(s):

Urology Times staff

Silver also outlines an example of a patient who he would treat with high-intensity focused ultrasound.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, David A. Silver, MD, shares his experience with high-intensity focused ultrasound (HIFU) and describes a sample case. Silver is chief of urology at Maimonides Medical Center in Brooklyn, New York.

      Related Videos
      Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
      Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
      Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
      Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
      Expert discusses the NMIBC trials landscape
      John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
      John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
      Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
      Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
      5 key trial insights from AUA 2025
      5 key trial insights from AUA 2025
      Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © - bongkarn - stock.adobe.com
      Experts discuss expanding use of vibegron for OAB
      John Michael DiBianco, MD, answers a question during a Zoom video interview
      John Michael DiBianco, MD, on silicone vs polyurethane stents for patients with kidney stones
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Related Content
      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
      May 6th 2025

      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

      Hannah Clarke
      Initial study results may be available as soon as the first half of 2026.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Published: April 29th 2025 | Updated: April 29th 2025

      Ultra-low PSA responses are more prevalent with darolutamide plus ADT

      Benjamin P. Saylor
      The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Stephen J. Freedland, MD
      April 28th 2025

      Most men in EMBARK trial recover T levels following treatment suspension

      Benjamin P. Saylor
      More than 80% of patients in both groups had a full recovery of testosterone.
      Stacy Loeb, MD, MSc, PhD | Credit: NYU Langone Health
      April 26th 2025

      TikTok, social media does more harm than good for prostate cancer education

      Patrick Campbell
      Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.
      © 2025 MJH Life Sciences

      All rights reserved.